Georgina Rizik brings with her 20 years of global commercialization expertise in oncology and specialty medicine, with a career in Biotechnology (Novartis, Roche, Boehringer Ingelheim, Ipsen) that spans executive leadership roles in global product/portfolio strategy, launch planning & operations, and country roles in marketing, sales, market access, new product planning and medical affairs. Georgina is a globally minded business leader with strategic and cultural agility having worked in Canada, Switzerland, Germany and the UK with extensive knowledge of the Canadian, European, US and international markets. Experienced in leading teams (matrix and direct management), these diverse roles have fostered Georgina’s entrepreneurial and collaborative skills.
An accomplished biopharmaceutical leader, Georgina has been recognized by PM360, as one of the 2017 PM360 ELITE 100 in the Strategist category. The PM360 ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the 100 most influential people in the healthcare industry.
Most recently, as Vice-President of Global Oncology – New Products & Strategy at Ipsen (London, UK), Georgina was accountable for the global commercialization strategy for pipeline products and informed key Go/No-Go decisions for external innovation opportunities, optimizing the business development approach.
As Global Commercial Head for the Oncology Biosimilars Franchise at Boehringer Ingelheim (Germany), Georgina built a unique Go To Market Strategy in an intensely competitive and dynamic market. She effectively steered the overall BI Biosimilars Brand Identity Strategy, Customer Experience Strategy and other best practice operational platforms to support adoption across the organization and within the affiliates.
As International Product Manager for Avastin® at Roche HQ (Basel, Switzerland), Georgina was responsible for developing global strategies and tactics for an indication (Breast Cancer) that generated almost 1 billion CHF in annual revenues. She effectively launched a label extension, in international markets, as well as repositioning the brand while leading a global cross-functional team, resulting in sales growth.
During her time in Canada with progressive operational roles at Roche and Novartis, Georgina led and executed award-winning strategies and tactical plans across solid tumors and hematologic malignancies, in addition to exceeding all KPIs. Georgina had the privilege to effectively contribute to the local and/or global success for the following blockbuster brands: Femara®, Gleevec®, Zometa®, Xeloda®, Herceptin® and Avastin®.
Georgina spent the first five years of her career as a Clinical Pharmacist in Canada and has a Bachelor of Science in Pharmacy (BScPhm) degree from the University of Toronto. In 2009, she earned her executive MBA from the Kellogg-Schulich EMBA Program.
Georgina is a purpose-driven and transformational leader who is passionate about making a difference to the lives of patients and doing her part in changing the paradigm of care within the healthcare ecosystem. In addition to her commitment to commercializing innovation in the healthcare sector to drive personalized care and a unique customer experience, Georgina is a mentor, educator and advisor who inspires and supports leaders and start-ups in the Healthcare/BioTech sector.